archerdx fusionplex pan solid tumor v2 kit (kit: ab0137) (Danaher)
90
Structured Review
Danaher
archerdx fusionplex pan solid tumor v2 kit (kit: ab0137)
Archerdx Fusionplex Pan Solid Tumor V2 Kit (Kit: Ab0137), supplied by Danaher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/archerdx+fusionplex+pan+solid+tumor+v2+kit+(kit%3A+ab0137)/archerdx+fusionplex+pan+solid+tumor+v2+kit++kit++ab0137+/10__1200_slash_po___24___00493-52-10-9
Average 90 stars, based on 1 article reviews
Archerdx Fusionplex Pan Solid Tumor V2 Kit (Kit: Ab0137), supplied by Danaher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/archerdx+fusionplex+pan+solid+tumor+v2+kit+(kit%3A+ab0137)/archerdx+fusionplex+pan+solid+tumor+v2+kit++kit++ab0137+/10__1200_slash_po___24___00493-52-10-9
Average 90 stars, based on 1 article reviews
archerdx fusionplex pan solid tumor v2 kit (kit: ab0137) - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Discovery of Gene Fusions in Driver-Negative Cancer Samples From the National Cancer Institute-Molecular Analysis for Therapy Choice Screening Cohort Article Snippet: PURPOSE The National Cancer Institute-Molecular Analysis for Therapy Choice (NCIMATCH) trial was implemented to identify actionable genetic alterations across cancer types and enroll patients accordingly onto treatment arms, irrespective of tumor histology.. Using multiplex polymerase chain reaction (PCR) nextgeneration sequencing, NCI-MATCH genotyped 5,540 patients, discovering gene fusions in 202/5,540 tumors (3.65%).. This result, substantially lower than the fusion detection prevalence of 8.5% across all patients with cancer screened at Massachusetts General Hospital’s (MGH) clinical laboratories, supported reanalysis of NCI-MATCH samples identified as mutations-of-interest (MOI)– negative. |